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Summary 
 
Integrin α5β1-mediated cell adhesion regulates a multitude of cellular responses, 
including cell proliferation, survival and cross-talk between different cellular signaling 
pathways. Integrin α5β1 is known to convey permissive signals enabling 
anchorage-dependent receptor tyrosine kinase signaling. Here we show that integrin α5 
functions as a negative regulator of epidermal growth factor receptor (EGFR) signaling 
through its N-glycosylation. In a mechanistic manner, integrin α5 forms a complex with 
EGFR and glycolipids in lipid rafts, resulting in a suppression of EGFR phosphorylation 
and internalization upon EGF stimulation. However, the expression of a mutant α5 that 
contained fewer N-glycans reversed the suppression of the EGFR-mediated signaling 
and cell proliferation. Consistent restoration of those N-glycans, particularly N-glycan 
on the potential N-glycosylation site 11 of integrin α5, re-instated the inhibitory effects 
as well as the complex formation with EGFR. These data are the first to demonstrate 
that EGFR activation can be regulated by the N-glycosylation of integrin α5, which is a 
novel molecular paradigm for the cross-talk between integrins and growth factor 
receptors. 
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Introduction 
 
Epidermal growth factor receptor (EGFR), a member of the ErbB receptor tyrosine 
kinase (RTK) family, converts extracellular cues into intracellular effectors, triggering 
appropriate cellular responses
1-3
, which plays a key role in normal epithelial 
developmental biology and in tumor metastasis
4
. A dysregulation of EGFR signaling, 
including receptor overexpression and/or activation, is a common feature in 
tumorigenesis
5
. Due to this aberrant activity in the pathology of cancer, EGFR has 
emerged as an attractive candidate for anticancer therapy
6
, which prompted us to 
examine the underlying molecular mechanisms for EGFR activation. 
EGFR activation forms a complex signaling network with several regulators, including 
related-cytoplasmic proteins, microRNAs, tyrosine kinase inhibitors (TKIs), and other 
coupled-receptors
7-9
. However, studies that address these direct or indirect regulations 
of EGFR have focused mainly on the inner membrane, particularly the cytoplasmic 
kinase domain of EGFR. The outer membrane underlying mechanisms remain 
unknown. 
Current insight into this regulation derives largely from studies around EGFR-related 
microdomains, so called lipid rafts
10-13
, which are thought to act as platforms for EGFR 
signaling
14, 15
. These molecules are localized in the microdomains of the cell membrane, 
and are usually rich in cholesterol, glycosphingolipids (GSLs), and glycoproteins
15-17
. 
Several studies have associated GSLs, including gangliosides GM1, GM3, and GD3, 
with the regulation of EGFR signaling
18-20
. In addition to GSLs, some glycoproteins that 
are located in the EGFR-related lipid rafts, play important roles in the regulation of 
EGFR signaling
12, 13, 21-23
. These limited results highlight the possibility that 
glycosylation might act as a ‘linker’ in lipid rafts for the regulation of EGFR. However, 
little is known about how glycosylation controls regulation. Therefore, elucidation of 
the underlying mechanisms involved in the glycosylation-mediated regulation of EGFR, 
is very important for a complete view of the biological functions of EGFR.  
Integrins, are important members of the EGFR lipid rafts-related glycoproteins, as 
mentioned above, and are major carriers of N-glycans, which are thought to play crucial 
roles in many biological functions. In response to cell adhesion, integrins not only 
directly initiate certain cytoplasmic signals for cell spreading, but also indirectly 
modulate the transmission of EGFR signaling, which is referred to as cross-talk
24-30
. The 
integrins mediate cooperation with EGFR mainly through α-cytoplasmic domains31, 
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which are also restricted to the inner membrane. Until recently, integrin α5β1, a major 
fibronectin receptor, was believed to be a well-characterized integrin, with 
N-glycosylation functions in cell adhesion
32, 33
. However, the function of 
N-glycosylation on cell proliferation and cellular signaling remains unclear. In fact, 
there have been several controversial reports about the regulation of EGFR-mediated 
signaling by integrin α534, 35.  
To resolve these issues, we have examined the relationship between integrin α5 and 
EGFR, and found that the expression of integrin α5 negatively regulates 
EGFR-mediated cellular signaling and cell proliferation. We used N-glycosylation 
mutants of integrin α5 to clarify the roles of the N-glycosylation of α5 in 
EGFR-mediated signaling and cross-talk with EGFR, and found that the regulation was 
strictly controlled via the N-glycans of integrin α5, particularly the N-glycans on 
potential N-glycosylation site 11. Our results clearly demonstrate the importance of the 
N-glycans of integrin in the regulation of EGFR-mediated cellular signaling, provide 
new insights into a novel therapeutic approaches for tumor treatment.  
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Results 
 
1. Inhibition of cell proliferation and tumor formation by the 
expression of integrin α5 via N-glycosylation.  
Given the evidence that integrin α5 cooperates with EGFR to drive cell-cycle 
progression
36
, we established a simple cell model to clarify the underlying molecular 
mechanism for the cooperation between integrin α5 and EGFR. First, human EGFR 
cDNA was transfected into the CHO-B2 cell line that lacks the α5 subunit, in order to 
establish a stable EGFR-overexpressed CHO-B2 cell line (CHO-B2/EGFR). The 
CHO-B2/EGFR cells then were respectively reconstituted with either a GFP-tagged 
wild-type (WT) or a N-glycosylation mutant α5 subunit, S3-5, either of which only 
contains three of the 14 N-glycosylation sites (Fig. 1A). The three sites on the 
β-propeller domain of integrin α5 are essential for α5β1 heterodimerization, cell surface 
expression, and cell adhesion in CHO-B2 cells
33
. As shown in Fig.1B, when analyzed 
by flow cytometry analysis and biotinylation, these cells exhibited almost the same 
expression levels of EGFR and α5β1 on the cell surface and in the whole-cell lysates, 
suggesting that the level of α5 subunits had no effect on the expression of EGFR. 
Unexpectedly, the expression of WT, but not S3-5 α5 subunits, significantly suppressed 
cell proliferation, compared with those found in control cells with or without 
overexpression of a GFP tag only (Fig. 1C). The colony formation consistently included 
colony numbers and sizes that were clearly decreased in the WT, compared with those 
in the S3-5 and control cells (Fig. 1D). Furthermore, the single colony size were also 
confirmed by the immunostaining (EV Fig. 1). 
These in vitro observations encouraged us to investigate the effects of α5 expression on 
tumorigenicity in vivo. As shown in Fig.1e, both GFP and S3-5 cells permitted vigorous 
tumor formation. Tumor formation was significantly suppressed, however, in the WT 
cells as reflected by both the tumor volume and weight. Taken together, these results 
suggested that the remaining N-glycosylation sites, with the noted exception sites 3-5 of 
integrin α5 play an important role in the inhibition of cell growth and tumorigenecity.  
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Figure 1. Effects of WT and S3-5 mutant α5 subunit expression on cell growth in 
CHO cells. (A) Schematic diagram of potential N-glycosylation sites on the WT and S3-5 
integrin α5 subunit. Putative N-glycosylation sites (N84Q, N182Q, N297Q, N307Q, N316Q, 
N524Q, N530Q, N593Q, N609Q, N675Q, N712Q, N724Q, N773Q, and N868Q) are indicated 
by triangles, and point mutations are indicated by crosses. (B) The Ctrl, GFP, WT, and S3-5 
cells exhibited same expression levels of EGFR and integrinα5β1. The stable cell lines were 
established as described under the ‘Materials and Methods’ section. The expression levels of 
integrin α5β1 and EGFR on the cell surfaces and in total cell lysates were analyzed by flow 
cytometry analysis (left panel) or biotinylation (right upper panel) and western blot (WB) with 
indicated antibodies (right lower panel), respectively. The IgG and α-tubulin were used as 
controls. (C) The WT, but not S3-5 transfectants exhibited a decrease in cell growth. After 
starvation for 24 h, cells were supplied with DMEM containing 10% FBS, and then cell 
numbers were counted and statistically analyzed at the indicated times (n=3). (D) The ability of 
colony formation was inhibited in WT, but not S3-5 cells. The representative images of cell 
colonies are shown in the left panel. Colonies were stained with crystal violet after 14 days of 
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seeding on plastic dishes. The OD595 values of GFP, WT, and S3-5 groups were normalized to 
that of the Ctrl group (n=3). (E) WT, but not S3-5 cells showed a decrease in the tumorigenicity 
in vivo. The indicated cells (1×10
6
) were injected subcutaneously into the left flank. Tumors 
were dissected and their volumes and weights were noted after 21 days (n=3). All values are the 
means ± s.e.m., Student’s t-test n.sP >0.05; *P <0.05; ***P <0.001. Scale bar, 1 cm (D), 1 cm 
(E). 
 
 
 
Expanded View Figure 1. Comparison of colony formation between CHO 
transfectants of WT and S3-5 mutant. The WT, but not S3-5 cells showed the smaller 
colonies, compared with the control cells. The mRFP-tagged stable cell lines (Ctrl-mRFP, 
GFP-mRFP, WT-mRFP, and S3-5-mRFP) were established as described in the ‘Materials and 
Methods’ section. 1000 cells were seeded on each coverslip. Images of representative single 
colonies were taken 14 days after seeding and subjected to immunofluorescence (IF) analyses 
(n=3). Cell nuclei were stained with TO-PRO-3 (blue). Merge panels show the merged GFP, 
mRFP, and TO-PRO-3 images. Scale bar, 120 µm. 
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2. EGFR-mediated cellular signaling is suppressed by the expression of 
wild-type integrin α5.  
Considering the overexpression of EGFR in these cells, we wondered whether 
EGFR-mediated cellular signaling was modulated by α5. Surprisingly, under normal 
culture conditions, the phosphorylation levels of EGFR and its downstream molecules 
ERK and AKT were significantly decreased in WT cells compared with those in other 
cells (Fig. 2A). Furthermore, the responses for exogenous EGF-induced cell 
proliferation (Fig. 2B) and cellular signaling (Fig. 2C) were also significantly 
suppressed in WT cells, but neither S3-5 cells nor in the other control cells.  
Integrin α5 also is known to cooperate with other GFRs, such as c-Met or VEGFR37, 
thus, we next investigated the contributions of EGFR to cell growth. Both the 
phosphorylation levels of EGFR and ERK were completely blocked in the presence of 
anti-EGFR blocking antibody (Fig. 2D). Surprisingly, the phosphorylation levels of 
AKT were reversely increased, suggesting that EGFR is a major upstream component 
for ERK activation, but not for AKT in the CHO-B2/EGFR cells. The abilities and 
differences among cells for cell proliferation were largely cancelled by treatment with 
anti-EGFR blocking antibody (Fig. 2E). Consistently, the growth ability differences 
between CHO-B2/WT and other cells in the CHO-B2 (low EGFR-expression) group 
were also significantly decreased compared with the CHO-B2/EGFR group (EV Fig. 2). 
These results supported our hypothesis that integrin α5 inhibits EGFR-mediated 
signaling via N-glycosylation. 
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Figure 2. Expression of WT, but not S3-5 integrin α5 inhibits EGFR-mediated 
cellular signaling. (A) The EGFR-related cellular signaling was inhibited in the WT cells. 
Cell lysates from the indicated cells were subjected to WBs with the indicated antibodies (left 
panel). The relative ratios (p-EGFR, p-ERK, and p-AKT versus EGFR, ERK, and AKT, 
respectively.) are shown in the right panel (n=3). (B) Comparison of cell growth among WT, 
S3-5 and control cells upon EGF stimulation. After starvation, cells were supplied with the 
complete medium with or without EGF (0. 1 ng/ml). Cell numbers were counted at the indicated 
times and statistically analyzed (n=3). (C) Expression of WT α5 decreased responses for EGF. 
After starvation for 24 h, cells were treated with EGF at the indicated concentrations for 5 min. 
WB analysis was performed with indicated antibodies. (D,E) Effects of the treatment with 
anti-EGFR-blocking Ab on EGFR-related cellular signaling (D) and cell growth (E). Cells were 
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cultured with complete medium containing 10 µg/ml IgG (control) or anti-EGFR-blocking Ab 
for 72 h, the resultant cell extracts were subjected to WB with the indicated antibodies (D) and 
the cell numbers were counted and statistically analyzed (n=3) (E), respectively. All values are 
the means ± s.e.m., Student’s t-test *P <0.05; **P <0.01; ***P <0.001. 
 
 
 
Expanded View Figure 2. Inhibitory effects of integrin α5 on cell proliferation are 
related with EGFR expression levels. The suppression of cell growth by integrin α5 was 
decreased in CHO-B2 cells which expressed endogenous EGFR at a lower level. These stable 
cell lines of CHO-B2/WT and CHO-B2/S3-5 were established as described under the ‘Materials 
and Methods’ section. All values are the means ± s.e.m., Student’s t-test *P <0.05; ***P <0.001. 
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3. Inhibitory effects of integrin α5 on cell growth and EGFR cellular 
signaling are also observed in several human cancer cell lines.  
As described above, α5 negatively regulated EGFR-mediated signaling via 
N-glycosylation in CHO-B2/EGFR cells. Therefore, we selected several human cancer 
cell lines, such as HeLa, U-251MG, and MDA-MB-231 cells, which express relative 
high levels of endogenous EGFR, in order to confirm whether the phenomenon is 
common to other mammalian cells. To eliminate influences from endogenous α5, that 
gene was deleted by using a CRISPR/Cas9 knockout system. The knockout efficiencies 
were confirmed by flow cytometric analysis and western blotting of HeLa (Fig. 3A,B), 
U-251MG, and MDA-MB-231 cells (EV Fig. 3A,B). As shown in Fig. 3C, the KO cells 
exhibited an increased proliferation ability compared with the parent cells, indicating 
that α5 also acts as a proliferation suppressor in HeLa cells. Furthermore, the α5-KO 
cells were reconstituted with a GFP tag, WT or S3-5, and each cell line showed similar 
expression levels of EGFR (Fig. 3D; EV Fig. 3C). Consistent with the data of CHO-B2 
cells, the expression of WT cells had an inhibitory effect on cell proliferation (Fig. 3E) 
and phospho-EGFR as well as subsequent downstream phosphor-ERK (Fig. 3F), which 
differed from the expression of S3-5 integrin α5 cells. Moreover, the responses to EGF 
were also attenuated in WT, compared with that in other cells (Fig. 3G). Almost the 
same tendencies were observed in the U-251MG and MDA-MB-231 cells (EV Fig. 
3D-I). Together, these results further suggest that integrin α5 is a negative regulator for 
EGFR-mediated signaling through N-glycosylation. To clarify the underlying molecular 
mechanism, we further employed CHO-B2/EGFR cells in subsequent experiments.  
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Figure 3. Expression of integrin α5 inhibits cell growth and EGFR cellular 
signaling in HeLa cells. (A,B) The efficiency of the knockout of the α5 gene using the 
CRISP/Cas9 system was confirmed by flow cytometric analysis (A) and WB (B). The integrin 
α5-KO HeLa cells were established as described in the ‘Materials and Methods’ section. (C) 
The α5 KO-HeLa cells exhibited an increase in cell growth. An analysis for cell growth was 
performed as described in (C) (n=3). (D) Expression levels of integrin α5β1 and EGFR on the 
cell surface were confirmed by flow cytometric analysis among revived cells with WT, S3-5 
mutant of α5 in the α5 KO-HeLa cells. (E) Comparison of cell growth among those 
transfectants. An analysis for cell growth was performed as described in the ‘Materials and 
Methods’ section (n=3). (F) The phosphorylation levels of EGFR and ERK were significantly 
suppressed in the WT cells, compared with the other cells. The left panel shows a representative 
WB pattern and the right panel displays the quantitative analysis (n=3). (G) The WT cells also 
exhibited attenuated EGFR responses upon EGF stimulation. The responses to indicated 
concentrations of EGF were performed as described above in Fig. 2C. All values are the means 
± s.e.m., Student’s t-test **P <0.01; ***P <0.001. 
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Expanded View Figure 3. Expression of integrin α5 inhibits cell growth and EGFR 
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cellular signaling in U-251MG and MDA-MB-231 cells. The relevant integrin α5-KO 
cells were established as described in the ‘Materials and Methods’ section. The established 
α5-KO U-251MG and MDA-MB-231 cells were confirmed by flow cytometry analysis (A) and 
WB (B). (C) The expression levels of integrin α5β1 and EGFR in the relevant integrin 
α5-rescued U-251MG and MDA-MB-231 cells were confirmed by flow cytometry analysis. The 
IgG and α-tubulin were used as controls. (D-I) These rescued cells with WT, but not S3-5, α5 
also exhibited growth retardations, decrease in EGFR signaling and attenuated EGF responses. 
These phenomena were similar to those observed in HeLa cells as shown in Fig.3. All values are 
the means ± s.e.m., Student’s t-test *P <0.05; **P <0.01; ***P <0.001. 
 
 
 
 
 
 
 
 
4. Expression of integrin α5 delays EGFR internalization upon EGF 
stimulation.  
Upon EGF binding, EGFR is involved in a series of trafficking events, including 
internalization, degradation, and recycling, which ultimately regulate its signal 
amplification and propagation
38
. Also, integrins are known to regulate the trafficking of 
some membrane proteins
39
. Therefore, we conducted a biotinylation-based 
internalization assay (Fig. 4A) and a Alexa Fluor
®
 555-conjugated EGF 
(EGF-555)-based EGFR endocytosis assay (Fig. 4B) in order to determine if the 
kinetics of EGFR internalization are affected by α5. To increase sensitivity for detection, 
primaquine, a receptor recycling inhibitor, was added to the culture media to block the 
recycling of internalized EGFR to the cell membrane. Of particular interest, the EGFR 
internalization after EGF treatment during the first 10-min duration was greatly retarded 
in the WT cells, compared with that in both the S3-5 and control cells, although the 
levels of the internalized EGFR were similar at the 15-min chase point. These results 
clearly indicated that EGFR internalization was delayed by α5 via N-glycosylation, 
which might explain why the EGFR signaling was inhibited in the WT cells.  
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Figure 4. Integrin α5 decreases EGFR internalization upon EGF stimulation. (A) 
The internalization of EGFR was inhibited in WT cells, compared with the other cells. A 
biochemical internalization assay of EGFR was performed, as described in the ‘Materials and 
Methods’ section. The internalized EGFRs at indicated times were immunoprecipitated by 
avidin-agarose, and then subjected to WB for detection of EGFR. The cell lysates were used as 
controls to show similar expression levels of EGFR among these cells. (B) The rates of 
internalized-EGFR were statistically analyzed (right panel, n=3). (C) The EGFR endocytosis 
was inhibited in the WT, but not S3-5 cells upon EGF stimulation. A representative image for 
EGFR endocytosis after 50 ng/ml EGF-555 treatment at the indicated times. The image was 
merged with EGF-555 and TO-PRO-3 staining. (D) The numbers of internalized EGF-555 
puncta per cell in random fields were quantified (n=9). All values are the means ± s.e.m., 
Student’s t-test *P <0.05; **P <0.01; ***P <0.001. Scale bar, 10 µm. 
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5. Integrin α5 interacts with EGFR and plays a critical role in its 
localization in lipid rafts.  
As described above, the N-glycosylation of integrin α5 regulated EGFR internalization 
and activation. Therefore, we wondered how N-glycosylation participates in regulation, 
and whether integrin α5 is associated with EGFR through the N-glycosylation of α5. 
Reciprocal immunoprecipitates with anti-GFP agarose and anti-EGFR antibody showed 
that integrin α5 indeed interacted with EGFR (Fig. 5A), which was consistent with 
previous reports
40
. This interaction was significantly decreased in the S3-5 cells, by 
comparison with WT (Fig. 5A). Confocal microscopy showed that the WT version of α5 
was highly co-localized with EGFR, while the S3-5 mutant, to a lesser extent, 
co-localized with EGFR (EV Fig. 4A). The decreased interactions between S3-5 
integrin and EGFR were also confirmed in HeLa, U-251MG, and MDA-MB-231 cells 
(EV Fig. 4B). These results suggest that the N-glycosylation of integrin α5 is required 
for the interaction between integrin α5 and EGFR. Next, we wondered whether this 
interaction is also modulated by EGF stimulation. As shown in Fig. 5B, the interaction 
was decreased following EGF stimulation both in WT and S3-5 cells. Additionally, the 
interaction was enhanced when those cells were attached to fibronectin-coated dishes, 
but it was decreased upon EGF stimulation. These results strongly suggested that the 
interaction of EGFR and integrin α5 restricts EGFR activation and decreases EGFR 
responsiveness upon EGF treatment.  
Given the evidence that EGFR localizes in the lipid rafts, which results in its signal 
transduction
10, 18, 41
, we speculated that the N-glycans on integrin α5 might affect the 
distribution of EGFR in the lipid rafts on a cell membrane. When using the OptiPrep 
density gradient ultracentrifugation method for lipid raft fractions, the EGFR and 
integrin α5 from each of the cell lines were basically distributed in the fractions ranging 
from 4–8, in which caveolin-1 (Cav-1), a marker for lipid raft, could be detected (Fig. 
5C). Interestingly, the distribution of EGFR and α5 was shifted from the low-density 
fractions (No. 4 and 5) in the WT cells to higher-density fractions (No. 6–8) in the S3-5 
and control cells, indicating that the N-glycans on integrin α5 may be a switch that 
influences EGFR and integrin α5 localization on the cell membrane. 
The glycosylation of integrin α5 could affect its translocation into or out of a 
glycosphingolipid-enriched microdomain
42
, thus we tested its association with 
ganglioside GM1 and EGFR in these cells. Co-immunoprecipitation using 
biotinylated-cholera toxin subunit-B (CTB), which specifically binds ganglioside GM1, 
showed that the association of EGFR and α5 was much higher in the WT cells than it 
was in either the S3-5 or the control cells (Fig. 5D). These interactions among GM1, 
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EGFR and α5 were completely disrupted in the presence of methyl-β-cyclodextrin 
(M-β-CD), a cholesterol depletion reagent. The results of confocal microscopy 
consistently showed that the co-localization of EGFR/CTB/α5 was significantly 
increased in WT cells compared with S3-5 cells (EV Fig. 4C). Taken together, these 
results clearly showed that the N-glycosylation of α5 plays a crucial role in its 
localization and complex formation with other receptors on the cell membrane.  
 
 
Figure 5. Integrin α5 associates with EGFR and regulates their localization in lipid 
rafts. (A) The association of integrin α5 with EGFR was decreased in S3-5 cells, compared 
with the WT cells. The indicated cell extracts were immunoprecipitated with anti-GFP agarose 
(left panels) or anti-EGFR antibodies (right panels), and then subjected to WB reciprocally 
followed by anti-EGFR and integrin α5 antibodies for detection. (B) The interaction between 
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integrin α5 and EGFR was decreased upon EGF stimulation. The cells were cultured on dishes 
coated with or without 10 µg/ml FN for 24 h, and then stimulated with or without EGF at 0.3 
ng/ml for 5 min. The resultant cell lysates (as an input, lower panels) were directly blotted with 
anti-EGFR and integrin α5 antibodies, or immunoprecipitated with anti-GFP agarose (upper 
panels), and then blotted with anti-EGFR antibody. (C) Comparison of localization of EGFR 
and integrin α5 in the lower-density lipid rafts. Distributions of integrin α5 and EGFR from 
indicated cell lysates in the lipid raft fractions were prepared as described in the ‘Materials and 
Methods’ section. Fraction No. 1 is the top fraction of the gradient, and No. 12 is the bottom 
fraction. The localization shifts of the integrin α5 and EGFR are highlighted with red dotted 
lines. The Cav-1 was used to act as a marker for lipid rafts. (D) The complex of EGFR and 
integrin α5 is mediated by GM1. The indicated cells were pretreated with or without M-β-CD 
(10mM) for 1 h. After the treatment, cell lysates were incubated with biotinylated-CTB for 
another 1 h, and then immunoprecipitated with avidin-agarose beads. The immunoprecipitates 
were subjected to WB detected with anti-EGFR and integrin α5 antibodies (upper panels). The 
whole cell lysates were also subjected to WBs with the indicated antibodies (lower panel; as an 
input). 
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Expanded View Figure 4.The complex formation of EGFR, α5, and GM1 is 
decreased in S3-5 cells. (A) The co-localization areas of integrin α5 and EGFR were 
decreased in S3-5 cells. The representative images of the localizations of α5 and EGFR in WT 
or S3-5 cells are presented in the left two panels. WT and S3-5 cells were cultured on coverslips, 
and then subjected to IF analyses. The images were immunofluorescently labeled for integrin 
α5-GFP (green) and EGFR (red). The percentage of EGFR spots that overlap with integrin α5 is 
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presented in graphic form (right panel, n=9). (B) The interaction between integrin α5 and EGFR 
was decreased in the HeLa, U-251MG, and MDA-MB-231 S3-5 mutant cells. The indicated cell 
extracts were immunoprecipitated with anti-GFP agarose (upper panels), and then subjected to 
WB followed by anti-EGFR and integrin α5 antibodies for detection in the HeLa, U-251MG, 
and MDA-MB-231 cells, respectively. Crude cell extracts were also subjected to WB as ‘input’ 
using the indicated antibodies (lower panels). (C) The co-localization areas of EGFR, GM1, and 
integrin α5 were decreased in S3-5 cells. The representative images of the localizations of 
EGFR, GM1, and integrin α5 in WT and S3-5 cells are presented (left panel). The WT and S3-5 
cells were stained with anti-EGFR antibody and Alexa Fluor
®
 555-conjugated CTB, and then 
subjected to IF analyses. EGFR, α5, and GM1 were shown as red, green, and purple, 
respectively. The percentage of the co-localization is presented in graphic form (right panel, 
n=9). All values are means ± s.e.m., Student’s t-test **P <0.01. Scale bar, 10 µm (A), 10 µm 
(C). 
 
 
 
 
 
 
 
 
6. N-glycosylation on the Calf-1,2 domain, particularly the potential 
N-glycosylation site No. 11 of integrin α5, is important for its inhibitory 
functions.  
The data provided above led us to seek the N-glycosylation site(s) of α5 that was 
essential for its growth inhibitory effect. Therefore, we focused on the N-glycosylation 
of the calf domain (No. 10-14) (Fig. 6A), which happens in the vicinity of the cell 
membrane. Restoration of N-glycosylation on the calf domain in the S3-5 mutant, 
S3-5,10-14, decreased cell proliferation, which was similar to that in WT cells (Fig. 6B). 
Furthermore, deletion of the N-glycosylation sites on the calf domain (Δ10-14) of α5 
abolished its inhibitory effects on cell growth (Fig. 6B). These results indicated that 
N-glycosylation on the No. 10-14 sites of α5 plays a crucial role in its inhibitory 
functions. Consistently, the levels of p-EGFR, p-ERK, and p-AKT in S3-5,10-14 cells 
were similar to those in the WT, but different from those in S3-5 or Δ10-14 cells (Fig. 
6C). The attenuated response to EGF in WT cells was also observed in S3-5,10-14, but 
not Δ10-14 cells (Fig. 6D). The decreased association with EGFR (Fig. 6E) and the 
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aberrant localization of EGFR and α5 in lipid rafts (Fig. 6F) in S3-5 cells could be 
reversed in the S3-5,10-14 cells, which was similar to the situation in the WT cells.  
To further characterize which potential N-glycosylation site(s) on the calf domain was 
important for the inhibitory functions, we re-expressed N-glycosylation one-by-one in 
the S3-5 mutant cells (S3-5,10; S3-5,11; S3-5,12; S3-5,13; and, S3-5,14) (EV Fig. 5A). 
All of these cell lines exhibited similar expression levels of EGFR and α5β1 on the cell 
surface and abilities for cell spreading on FN, compared with those in the S3-5 cells 
(EV Fig. 5B,C). However, cell proliferation was partially inhibited in the S3-5,10; 
S3-5,11; and, S3-5,12 cells, but not in the other two mutant cells (S3-5,13 and S3-5,14), 
compared with those in the S3-5 cells. In particular, the inhibitory effect on cell growth 
in the S3-5,11 cells was similar to the WT of α5 (Fig. 7A). Consistently, the aberrant 
expression levels of p-EGFR and its-mediated signaling in the S3-5 cells were 
completely revived in the S3-5,11 cells (Fig. 7B). The association between EGFR and 
integrin α5 was greatly increased in the S3-5,11 cells, comparable to those in the WT or 
S3-5,10-14 cells (Fig. 7C). The localization of EGFR and α5 in lipid rafts could also be 
reversed in S3-5,11 cells, which was similar to the WT cells (Fig. 7D).  
Moreover, the significance of the potential N-glycosylation site No. 11 on integrin α5 
was further investigated using the Δ11 cells (EV Fig. 5A). The Δ11 cells exhibited 
similar expression levels of EGFR and α5β1 on the cell surface, as well as abilities for 
cell spreading on FN, compared with other mutant cells (EV Fig. 5B,C). It is 
noteworthy that the inhibitory effect of α5 on cell growth was cancelled by the deletion 
of the No. 11 N-glycosylation site on α5 (Fig. 7E). Taken together, these results clearly 
showed that the No. 11 N-glycosylation of integrin α5 plays a crucial role in the 
regulation of EGFR-mediated cell signaling, which demonstrates a novel regulator for 
EGFR inhibition. 
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Figure 6. N-glycosylation on the Calf-1,2 domain of integrin α5 mediates its growth 
inhibitory function. (A) Schematic diagram of potential N-glycosylation mutational integrin 
α5 subunit (WT; S3-5, Δ10-14; and, S3-5,10-14). (B) The S3-5,10-14, but not Δ10-14 cells 
exhibit a similar inhibitory ability for cell growth, compared to the WT cells. The stable 
rescued-cell lines (Δ10-14 and S3-5,10-14) were also established as described in the ‘Materials 
and Methods’ section. The cell growth abilities of WT, S3-5, Δ10-14, and S3-5,10-14 were 
analyzed as described in Fig. 1C. (n=3). (C) The EGFR-related cellular signaling was revived in 
the S3-5,10-14 cells. Cell lysates from the indicated cells were subjected to WBs with indicated 
antibodies (left panel). The relative ratios were statistically analyzed (right panel, n=3). (D) The 
response to EGF is decreased in S3-5,10-14 cells. Cells were serum-starved for 24 h followed 
by a treatment with indicated concentrations of EGF for 5 min and then the resultant cell 
extracts were subjected to WB analysis with indicated antibodies. (E) The interaction between 
integrin α5 and EGFR has been also rescued in the S3-5,10-14 cells. The indicated cell extracts 
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were immunoprecipitated with anti-GFP agarose followed by anti-EGFR and α5 antibodies for 
WB (upper panels). The whole cell extracts were also subjected to WB using the indicated 
antibodies (lower panels; as an input). (F) The localizations of EGFR and integrin α5 in the 
lower-density lipid raft were also revived in the S3-5,10-14 cells. Distributions of integrin α5 
and EGFR in lipid raft fractions were detected, as described in Fig. 5C. The localization shifts 
of integrin α5 and EGFR are highlighted with red dotted lines. The Cav-1 was used to act as a 
positive control for lipid rafts. All values are the means ± s.e.m., Student’s t-test **P <0.01; 
***P <0.001. 
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Figure 7. The No.11 N-glycosylation on integrin α5 is the most important one for 
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it-mediated growth inhibitory function. (A) The S3-5,11 cells exhibit comparable 
inhibitory ability for cell growth to the S3-5,10-14 ones. The stable expression cell lines of 
S3-5,10; S3-5,11; S3-5,12; S3-5,13; and, S3-5,14 mutants were established, as described in the 
‘Materials and Methods’ section. The cell growth abilities of the mutant cells were analyzed, as 
described in Fig. 1C (n=3). (B) The EGFR-related cellular signaling was also revived in the 
S3-5,11 cells. Cell lysates from the indicated cells were subjected to WB with indicated 
antibodies (left panel). The relative ratios were statistically analyzed (right panel, n=3). (C) The 
interaction between integrin α5 and EGFR was also revived in the S3-5,11 cells. The indicated 
cell extracts were immunoprecipitated with anti-GFP agarose and followed by anti-EGFR and 
α5 antibodies for WB (upper panels). The whole cell extracts were also subjected to WB using 
indicated antibodies (lower panels; as an input). (D) The localizations of the EGFR and integrin 
α5 in the S3-5,11 cells can also be revived in the lower-density lipid raft. Distribution of integrin 
α5 and EGFR from the indicated cell lysates in the lipid raft fractions were detected as 
described in Fig. 5c. The localization shifts of integrin α5 and EGFR are highlighted with red 
dotted lines. The Cav-1 was used to act as a positive control for lipid rafts. (E) The cell growth 
of Δ11 cells is significantly increased compared with WT cells. The abilities for cell growth 
were compared among the WT, S3-5, and Δ11 cells (n=3). All values are the means ± s.e.m., 
Student’s t-test **P <0.01. 
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Expanded View Figure 5. The integrin α5 mutant cells exhibit almost same 
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expression levels of α5β1 and EGFR on cell surface and abilities of cell spreading, 
compared with the WT ones. (A) Schematic diagram of potential N-glycosylation 
mutational integrin α5 subunits (WT; S3-5; Δ10-14; S3-5,10-14; S3-5,10; S3-5,11; S3-5,12; 
S3-5,13; S3-5,14; and, Δ11). (B) The integrin α5 mutant cells express equally α5β1 and EGFR 
levels on cell surface, compared with the WT cells. The expression levels of both α5β1 and 
EGFR on cell surface were analyzed by flow cytometry analysis. The IgG was used as a control. 
(C) The α5 mutant cells exhibited comparable abilities for cell spreading as WT ones. Cells 
were detached and then replanted on the FN-coated dishes. After incubation for 20 min, cells 
were fixed and the representative images were taken. The percents of the rounded, spread, and 
elongated cells were statistically analyzed (right bottom panel, n=9). All values are means ± 
s.e.m., Student’s t-test, n.sP >0.05. Scale bar, 120 µm (C). 
 
 
Figure 8. Proposed molecular mechanism for the regulation of EGFR cellular 
signaling by the N-glycosylations of integrin α5. In the integrin α5 with N-glycosylation 
on its Calf domain cells (especially N-glycosylation No. 11, left side), integrin α5β1 forms a 
complex with EGFR as well as glycosphingolipids in lipid raft, which may restrict the EGFR 
internalization and the related signaling upon EGF stimulation, resulting in an inhibition of cell 
proliferation. However, in the integrin α5-deficient or mutant (deletion of N-glycosylation on 
No.11 site) cells (right side), the majority of EGFR are located in lipid rafts without integrin α5, 
leading to a rapid activation and internalization of EGFR upon EGF stimulation. The thick 
arrow lines indicate a rapid EGF response and strong signal transduction, while the thinner 
arrow lines indicate these events are inhibited. 
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Discussion 
 
We described here how cell growth could be downregulated by integrin α5, and clearly 
demonstrated how the N-glycosylation of α5 is a key factor for regulation. Among 14 
potential N-glycosylation sites of α5, site 11 on the calf domain played a crucial role in 
the inhibitory effect on EGFR-mediated signaling, through regulation of the complex 
formation between EGFR and α5, localization in lipid rafts, and internalization (Fig. 8). 
Thus, the present study outlines the novel underlying mechanism responsible for the 
inhibition of EGFR, and also provides new insight into the role of N-glycosylation in 
the regulation of cellular signaling to maintain cell properties via a cross-talk manner 
among glycoproteins on the cell surface. 
Integrin α5 is thought to play crucial roles in many biological functions, but there are 
several controversial reports concerning the functions of integrin α5 in cancer. Low 
expression levels of α5 have been linked to the growth of tumors in gastric, colorectal, 
colon, and breast cancers
43
, while the overexpression of integrin α5 inhibited cell 
growth in several cell lines, such as 4T1, HT29 and CHO
44-48
. Furthermore, integrin α5 
has been used to downregulate the HER2, also named EGFR2, pathway in Caco-2 and 
HT-29 cells
34
. However, these findings are contradicted by other studies showing that 
integrin α5 functions as an oncogene and was associated with several instances of 
tumorigenesis
49, 50
, as well as promoting EGFR activation in some cancer cells
35, 40, 51
. 
The reasons for the contradictions in the functioning of α5 in cancers remain unclear. Of 
course, it could be speculated that α5 might differentially affect cellular signaling in 
different cell types or may exhibit intrinsic limitations in different cell models. However, 
based on our observation, integrin α5 inhibits cell proliferation through a negative 
regulation of EGFR via N-glycosylation, and shows tumor suppressor-like activity. 
Coincidently, similar to integrin α5, integrin α1 also negatively regulated EGFR26. We 
believe that the different effects of α5 on cell growth can be ascribed to distinct 
N-glycosylations, which may be altered in different cells and tissues and cancers. In fact, 
as shown in Fig. 7, removal of one N-glycosylation site (No. 11) alone abolished the 
inhibitory effects on EGFR.  
The N-glycosylation of integrin α5 plays crucial roles in several biological functions 
including cell adhesion and cell migration. However, little is known about the 
functioning of individual N-glycosylation. We previously underscored the importance of 
N-glycans on N-glycosylation potential sites 3-5 of α5 in its assembly of ß133. Although 
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the interaction-mediated cross-talk between α5 and EGFR was described previously37, 40, 
the precise underlying mechanisms of how α5 regulates EGFR signaling, and the 
molecular basis for this interaction, remains unclear. In the present study, we found that 
the N-glycosylation on the calf domain is essential for integrin α5/EGFR complex 
formation and is a key regulator for EGFR-mediated signaling. Most studies have 
focused on the cytoplasmic domain of integrins for the regulation of cell functions. For 
example, Caswell,P., et al. reported that the Rab-coupling protein could mediate the 
complex formation between integrin α5 and EGFR through their cytoplasmic domains 
to regulate cell migration
52
; Mattila, E., et al. described how integrin α1 negatively 
regulates EGFR-mediated cellular signaling through the activation of a protein tyrosine 
phosphatase in the cytosol
26
. These theories are plausible, since any output (downstream) 
must happen inside cell. However, these explanations are insufficient to clarify the 
molecular mechanisms in detail. In the present study, we highlighted an input 
(upstream), post-translational modification of the extracellular domains of α5, and 
showed its importance in complex formation and cellular signaling. Similar to integrin 
α5, we previously showed how the N-glycosylation on integrin ß4 regulates its 
association with EGFR and EGFR signaling
12
. Recently, Paszek, MJ., et al. 
demonstrated that a bulky glycocalyx in ECM might facilitate integrin clustering and 
then promote a tumor phenotype by increasing integrin adhesion and signaling
22
. Those 
results further support the notion that glycosylation plays an important role in 
protein-protein interaction
53
. 
It is worth noting that the N-glycans on the calf domain of α5 represent a key switch for 
the regulation of EGFR-mediated signaling. Previous study of the crystal structure of 
the ectodomain of integrin α5β1 showed that the N-glycans on α5, particularly those 
surrounding the RGD-binding pocket, play an important role in its binding to 
fibronectin
54
. Thus, based on molecular modeling, we speculate that the N-glycans of a 
calf domain may not participate in the cell adhesion process, but, instead, a location 
nearby the cell membrane suggests that they may be involved in the association with 
other molecules on the cell surface. In fact, restoration of all N-glycosylation sites on 
the calf domain (sites 10-14) in an S3-5 mutant completely rescued the complex 
formation and the capacity for inhibitory effects of EGFR-mediated signaling, which 
were observed in wild-type α5-expressing cells. Furthermore, N-glycosylation site No. 
11 is the most important site for these functions, which suggest that the N-glycan on site 
11 may have a specific structure and/or that it may be the appropriate distance for 
complex formation. In consideration of specific conformation of integrin α5β1 is 
essential for its-mediated effective functions
55-57
, future studies will require an extensive 
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analysis of the structures of these N-glycosylation mutants as well as that of specific 
N-glycans on individual sites. 
It is well known that an appropriate lipid raft formation is required for normal EGFR 
signaling transduction
58, 59
. We demonstrated here that N-glycosylation on integrin α5 
serves as a regulator for its association with EGFR and GM1, one of the gangliosides in 
lipid rafts, which regulates the EGF response. In fact, other gangliosides such as GM3 
and GD3 could also interact with the N-glycans on EGFR, and regulate EGFR signaling, 
indicating the importance of the carbohydrate-to-carbohydrate interaction in cellular 
signaling
12, 18, 20, 58, 59
. These results led us to speculate that the N-glycans on site 11 
could be the most suitable for those interactions among the α5, EGFR and gangliosides 
at a distance. Of course, more evidence is needed to prove this hypothesis. Although the 
underlying mechanism for the complex formation that downregulats EGFR 
internalization upon EGF stimulation remains unclear, the observation could partly 
explain why the cell growth was inhibited in the wild-type α5 cells, since enhancement 
of EGFR internalization and recycling plays an important role in signal transduction for 
persistent proliferation and tumor carcinogenesis in cells
38, 60
.  
Given the existence of the mutations of several integrins and EGFR during pathological 
processes
61-63
, particularly the N-glycosylation mutation of integrin α364, and the 
apparent irregular expression of integrin α5 in multiple tumors43, 49, 50, it is tempting to 
speculate that the N-glycosylation of integrin α5 may undergo mutations during 
tumorigenesis. Integrin α5 modified by different N-glycosylations exhibited different 
effects on cell proliferation and tumorigenesis, suggesting a possibility that the 
remodeling of N-glycosylation on this integrin may serve as a novel approach to tumor 
treatment. Furthermore, the present study clearly demonstrated how specific 
N-glycosylation on integrin α5 functions as a negative regulator for EGFR, which may 
provide a new perspective on the cross-talk between GFRs and integrins.  
30 
 
Materials and Methods 
 
1. Antibodies and reagents.  
The experiments were performed using the following antibodies: monoclonal antibodies 
(mAbs) against integrin α5 (610634), ERK1 (610031) and caveolin-1 (610407) that 
were obtained from BD Biosciences; the mAbs against human α5β1 (MAB1999) was 
from Millipore; mouse pAb to EGFR (Sc-120) was from Santa Cruz Biotechnology; 
rabbit mAbs to EGFR (#4267), p-EGFR (#3777), p-ERK1/2 (#4370), AKT (#9272), and 
p-AKT (#4060) were from Cell Signaling Technology; and, mAb against α-tubulin was 
from Sigma. Alexa Fluor
®
 647 goat anti-mouse IgG was obtained from Invitrogen (Life 
Technologies). The peroxidase-conjugate goat antibody against mouse and rabbit IgG 
were obtained from Promega and Cell Signaling Technology, respectively. The 
methyl-β-cyclodextrin (M-β-CD), biotin conjugated-cholera toxin B subunit (CTB), 
primaquine (PQ), MesNa, iodoacetamide and fibronectin (FN) were from sigma; the 
EGF (AF-100) was from PeproTech; the EGF-Alexa Fluor
®
 555 and cholera toxin 
subunit B (CTB)-Alexa Fluor
®
 555 were from Insvitrogen; the control mouse IgG1 was 
from TONBO biosciences; the Sulfo-NHS-SS Biotin was from Thermo Scientific; and 
the TO-PRO-3 was from Molecular Probes. The agarose-conjugated anti-green 
fluorescent protein (GFP) antibody (RQ2) and the Streptavidin-conjugated agarose were 
obtained from Medical & Biological Laboratories Co. Ltd. (Nagoya, Japan) and 
Millipore, respectively.   
 
2. Cell lines and cell culture.  
The 293T and HeLa cell lines were provided by the RIKEN cell bank (Japan). The 
phoenix and MDA-MB-231 cell lines were purchased from ATCC. The integrin α5 
subunit-deficient CHO-K1 cell line (CHO-B2) and the U-251MG cell line were gifts 
from Dr. Rudolf Juliano (School of Medicine, University of North Carolina, Chapel Hill, 
NC)
65
 and Prof. Jun Nakayama (Shinshu University Graduate School of Medicine, 
Japan), respectively. The stable cell lines used in this study, which are listed in Table 1, 
were established as mentioned below. All cell lines were maintained at 37 °C in 
Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine 
serum (FBS), under a humidified atmosphere containing 5% CO2, except for the virus 
production. 
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Parent 
cell lines 
α5-deficient 
cell lines 
GFP-rescued 
Cell lines 
WT α5-rescued 
Cell lines 
S3-5 α5-rescued 
Cell lines 
 CHO-B2 CHO-B2/GFP CHO-B2/WT CHO-B2/S3-5 
 CHO-B2/EGFR CHO-B2/EGFR/GFP CHO-B2/EGFR/WT CHO-B2/EGFR/S3-5 
 CHO-B2/EGFR-mRFP CHO-B2/EGFR-mRFP/GFP CHO-B2/EGFR-mRFP/WT CHO-B2/EGFR-mRFP/S3-5 
HeLa HeLa-α5KO HeLa-α5KO/GFP HeLa-α5KO/WT HeLa-α5KO/S3-5 
U-251MG U-251MG-α5KO U-251MG-α5KO/GFP U-251MG-α5KO/WT U-251MG-α5KO/S3-5 
MDA-MB-231 MDA-MB-231-α5KO MDA-MB-231-α5KO/GFP MDA-MB-231-α5KO/WT MDA-MB-231-α5KO/S3-5 
α5 mutants cell lines 
CHO-B2/EGFR/S3-5,10-14 CHO-B2/EGFR/Δ10-14 CHO-B2/EGFR/S3-5,10 CHO-B2/EGFR/S3-5,11 
CHO-B2/EGFR/S3-5,12 CHO-B2/EGFR/S3-5,13 CHO-B2/EGFR/S3-5,14 CHO-B2/EGFR/Δ11 
Table 1. List of the cell lines used in this study 
 
3. Generation of CRISPR/Cas9-based integrin α5-knockout(KO) cells.  
The CRISPR/Cas9-based integrin α5-KO cells were established as described 
previously
66
. Briefly, the sgRNA-specifying oligo sequences spanning human integrin 
α5 exon 3 were chosen from the human KO library sgRNAs67, which are listed in Table 
2. After annealing, the double-stranded guide oligos were cloned into the 
pSpCas9(BB)-2A-GFP (Addgene plasmid ID:48138) vector. The expression vector was 
transfected into the indicated cell lines by electroporation according to the 
manufacturer’s instructions. The GFP-positive cells were sorted by FACSAria II (BD 
Bioscience) after culture for 3 days. The integrin α5 positive, but GFP-negative, cells 
were then sorted 3 times during the following 2-week culture. The α5-KO cells were 
confirmed by flow cytometry analysis and western blot analyses as described below. 
 
4. EGFR and integrin α5 expression vectors.  
The cDNA of human EGFR (a generous gift from Dr. Motoko Takahashi, Sapporo 
Medical University, Japan) was inserted into a cloning entry vector (pENTR1A, 
Invitrogen) tagged with or without mRFP at the C terminus according to the 
manufacturer’s protocol of the in-fusion kit (Takara Bio). The vectors of GFP and 
GFP-tagged integrin α5 with altered N-glycosylation sites (WT, S3-5, and Δ10-14) were 
previously established in our laboratory
33
. The mutation vectors (S3-5,10; S3-5,11; 
S3-5,12; S3-5,13; S3-5,14; and, Δ11) and S3-5,10-14 were constructed using a 
site-directed mutagenesis kit (Takara Bio) and an in-fusion kit according to the 
manufacturer’s instructions, respectively. The resultant cDNAs were sequenced to 
confirm the presence of the desired mutations. We used the Gateway
TM
 cloning System 
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kit (Invitrogen) to acpuire all the expression vectors. Briefly, the LR clonase enzyme 
(Invitrogen) was used to transfer the cDNAs of EGFR and integrin α5 from the entry 
vectors into pBABE-puro-Rfa
32
 and CSII-CMV-Rfa (kindly provided by Dr. H. Miyoshi, 
Riken, Tokyo, Japan), respectively. The primers used for in-fusions and site-directed 
mutagenesis are listed in Table 2. 
 
Name Primer Sequence (5'-3') 
Primers used for In-Fusion 
EGFR(pENTR1A)-Sense ATCCGGTACCGAATTCACCATGCGACCCTCCGG 
EGFR(mRFP)-Antisense CTCGGAGGAGGCCATTGCTCCAATAAATTCACTG 
mRFP(EGFR)-Sense GAATTTATTGGAGCAATGGCCTCCTCCGAGGA 
mRFP(pENTR1A)-Antisense GTGCGGCCGCGAATTTTAGGCGCCGGTGGAGT 
ITGA5 (S10-14)-Sense TACATTATCAGAGCAAGAGCCG 
ITGA5 (S10-14)-Antisense ATCCAACTCCAGGCCCTTTGGG 
ITGA5 S(S10-14)-Sense CAAAGGGCCTGGAGTTGGAT 
ITGA5 S(S10-14)-Antisense GCTCTTGCTCTGATAATGTAGG 
Primers for Site-directed Mutagenesis 
ITGA5 S10-Sense GCCCTGAACCTCACTTTCCATGCCCAGAATG 
ITGA5 S10-Antisense AGTGAGGTTCAGGGCATTCTTGTCACCCA 
ITGA5 S11-Sense CCAGGGAACTTCTCCAGCCTGAGCTGTG 
ITGA5 S11-Antisense GGAGAAGTTCCCTGGGTGTCTGACGAGT 
ITGA5 S12-Sense GCCGTGAACCAGAGCCGCCTGCTGGTGT 
ITGA5 S12-Antisense GCTCTGGTTCACGGCAAAGTAGTCACAGCTC 
ITGA5 S13-Sense AATCTCAACAACTCGCAAAGCGACGTGG 
ITGA5 S13-Antisense CGAGTTGTTGAGATTCTTGCTGAGGATCTGG 
ITGA5 S14-Sense GGACTCAACTGCACCACCAATCACCCCA 
ITGA5 S14-Antisense GGTGCAGTTGAGTCCCGTAACTCTGGTC 
ITGA5 Δ11-Sense CCAGGGCAGTTCTCCAGCCTGAGCTGTG 
ITGA5 Δ11-Antisense GGAGAACTGCCCTGGGTGTCTGACGAGT 
Primers for KO  
ITGA5 KO-Sense CACCGGGGCAACAGTTCGAGCCCA 
ITGA5 KO-Antisense AAACTGGGCTCGAACTGTTGCCCC 
Table 2. List of the primers used in this study 
 
5. Virus production and infection.  
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The virus production and infection was performed as described previously
32, 68
. In brief, 
the pBABE-puro-Rfa-based retrovirus vectors and pLP/VSVG (Invitrogen) were 
transfected into Phoenix cells with Lipofectamine 2000 (Invitrogen). The 
CSII-CMV-Rfa-based lentivirus vectors were cotransfected with pCAG-HIVgp and 
pCMV-VSV-G-RSV-Rev into 293T cells. After transfection for 48 hours, the retrovirus 
and lentivirus supernatants were collected. The CHO-B2 cells were infected with the 
resultant viral supernatant containing 10 μg/ml Polybrene (Sigma) at 32 °C overnight 
and then selected in the presence of 2.0 mg/ml puromycin (Nacalai Tesque, Kyoto, 
Japan) for 7 days. The antibiotic-resistant positive colonies (CHO-B2/EGFR or 
CHO-B2/EGFR-mRFP) were picked up as a control. In the case of CHO-B2/EGFR or 
CHO-B2/EGFR-mRFP cells expressing GFP and integrin α5 mutants, the GFP-positive 
cells were sorted 3 times using FACSAria II after lentivirus infection for 72 h. The 
stable cell lines were used in subsequent studies.  
 
6. Western blot (WB) and immunoprecipitation (IP).  
For WB, the indicated cells were washed with ice-cold PBS and then lysed in the cell 
lysate (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100) with protease and 
phosphatase inhibitors (Nacalai Tesque, Kyoto, Japan) for 30 min. After centrifugation 
at 1,000 × g for 10 min, the supernatant was collected and protein concentrations were 
determined using a BCA protein assay kit (Pierce). The protein lysates were subjected to 
SDS-PAGE. After electrophoresis, the proteins were transferred to a PVDF membrane 
(Millipore) and detected with indicated primary and secondary antibodies using an 
Immobilon Western Chemiluminescent HRP Substrate (Millipore), according to the 
manufacturer’s instructions. For immunoprecipitates, cells were lysed with 
detergent-free TBS buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl) by being passed 
through a 21-G needle as described previously
18
. Briefly, cells were resuspended in the 
TBS with protease and phosphatase inhibitors and lysed by being passed through a 21-G 
needle 30 times. After centrifugation at 1,000 × g for 10 min, the supernatant was 
collected. The remaining pellet was again syringed 30 times. After centrifugation at 
1,000 × g for 10 min, the second postnuclear supernatant was combined with the first. 
The supernatants were immunoprecipitated with anti-GFP-agarose, anti-EGFR antibody 
or CTB-biotin and Streptavidin-conjugated agarose for 1 h at 4 °C with rotation, then 
the immunoprecipitates were washed twice with lysis buffer and subjected to 6% 
SDS-PAGE. 
 
7. Cell growth analysis.  
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The growth of the indicated cells was estimated by determination of cell growth curves 
or colony formation assays. To assay the cell growth curves, the cells (3×10
4
) were 
seeded in 6-cm dishes overnight and then serum-starved for either 24 or 48 h (for 
MDA-MB-231 cells). After starvation, the cells were supplied with DMEM containing 
10% FBS with or without EGF (0.1 ng/ml) or control IgG (10 µg/ml) or 
anti-EGFR-blocking Ab (10 µg/ml). The photos of the same areas on the cultured dishes 
were taken at the indicated times (0, 24, 48, and 72 h), and the cell numbers were 
counted. Cell numbers were normalized to those at 0 h and statistically analyzed. 
To assay the colony formation, either the Ctrl, GFP, WT, and S3-5 group or the 
Ctrl-mRFP, GFP-mRFP, WT-mRFP, and S3-5-mRFP group cells (0.6×10
3
 or 0.1×10
3
) 
were seeded in the 6-cm dishes or glass coverslips (MatTek Corporation, Ashland, MA), 
respectively. Cells were incubated for 14 days to allow colony formation, and were 
stained with 0.25% crystal violet for 15 min and images were taken. Quantification of 
the colonies was obtained by measuring the optical density at 595 nm (OD595) after 
digesting the colonies in each dish with 1 ml of 10% acetic acid. The OD595 values from 
GFP, WT, and S3-5 were normalized to that of the control cells. The colonies formed on 
the glass coverslips were obtained by immunofluorescence, as mentioned below. 
 
8. Cell surface biotinylation.  
Cell surface biotinylation was performed as described previously with minor 
modifications
33
. Briefly, cells were gently washed twice with PBS, and then incubated 
with ice-cold PBS containing 0.2 mg/ml Sulfo-NHS-SS Biotin for 1 h at 4 °C. After 
incubation, cells were washed 3 times with ice-cold PBS, and the cells were harvested 
and lysed in the lysis buffer. The biotinylated proteins were precipitated with 
Streptavidin-conjugated agarose, and then detected by WB, as described above. 
 
9. Flow cytometric analysis.  
Flow cytometric analysis was performed as described previously
32
. Briefly, 
semi-confluent indicated cells were detached from the 10-cm culture dishes using 
trypsin containing 1 mM EDTA and were subsequently stained with either the mouse 
IgG or primary mouse anti-α5β1 or anti-EGFR antibody for 1 h on ice, followed by 
incubation with Alexa Fluor
®
 647 goat anti-mouse IgG for 1 h. During the incubation, 
the cells were mixed gently every 10 min by flicking. After incubation, cells were 
washed 3 times with PBS, and then analyzed using FACSCalibur flow cytometer and 
Cell Quest Pro software (BD Biosciences). 
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10. Isolation of detergent-free lipid raft fractions.  
Preparation of detergent-free lipid raft fractions was preformed as described previously, 
with minor modifications
18
. Briefly, 150-mm dishes of indicated cells were washed 
twice with PBS, then lysed twice with a total of 1 ml (each time 0.5 ml) of 
detergent-free base buffer (20 mM Tris·HCl, 250mM sucrose at pH 7.8, containing 1 
mM CaCl2 and 1 mM MgCl2) with protease and phosphatase inhibitors by being passed 
through a 21-G needle as described above. After centrifugation at 1,000 × g for 10 min, 
the postnuclear supernatant (~1 ml) was mixed with the same volume of the base buffer 
containing 50% (vol/vol) OptiPrep, and then added to the bottom of a 5-ml 
ultracentrifuge tube. Subsequently, each 0.6 ml of 20, 15, 10, 5, and 0% of OptiPrep in 
the base buffer was sequentially overlaid to the ultracentrifuge tube. The gradient was 
centrifuged at 5.2 × 10
4
 rpm for 18 h at 4°C, using an ultracentrifuge (Hitachi himac 
CS100GX). A total of 12 fractions (0.4 ml for each) were carefully collected from top to 
bottom of the gradient, and analyzed by WB, as described above. 
 
11. Cell-spreading assays.  
The cell spreading assays were performed as described previously with minor 
modifications
33
. Briefly, 6-well plates were coated with FN (10 µg/ml) in PBS overnight 
at 4 °C and then blocked with 1% bovine serum albumin (BSA) in DMEM for 1 h at 
37 °C. The indicated cells were detached and suspended in serum-free DMEM with 0.1% 
BSA at 3 × 10
4
 cells/ml. After replating on the FN-coated dishes for 20 minutes, 
non-adherent cells were removed by washing with PBS, and the attached cells were 
fixed with 4% paraformaldehyde (PFA) in PBS, and representative photos were then 
taken by phase contrast microscopy. 
 
12. Immunofluorescence.  
To assay the immunofluorescence-based colony formation, the colonies in formed-glass 
coverslips, as mentioned above, were fixed in 4% PFA for 20 min at room temperature 
(RT) followed by 2 rinses with PBS. A non-specific blocking solution was applied 
(PBS/0.1% Triton X-100/10% BSA) at RT for 1 h followed by incubation with 
TO-PRO-3 for 1 h in the dark. Cells were washed 3 times with PBS, and were then 
immediately mounted using a fluorescent mounting medium (Dako). The confocal 
images were acquired using a 10×/0.4 NA objective lens (FV1000; Olympus). 
To assay the EGF-Alexa 555-based EGFR endocytosis, the indicated cells were grown 
on coverslips and starved for 24 h followed by a stimulation with serum-free medium 
containing 50 ng/ml EGF-555 and 0.3mM PQ, a recycling inhibitor, for the indicated 
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times (0, 2.5, 5, 10, and 15 min). Cells were washed, fixed, blocked, and labeled with 
TO-PRO-3 for 1 h in the dark followed by a mounting as described above. The confocal 
images were acquired using a 60×/1.35 NA oil immersion objective lens. The number of 
internalized EGF-555 puncta per cell and the percentage of cells with EGF-555 in 
random fields was quantified. 
To measure the co-localization of EGFR/integrin α5 or EGFR/GM1/integrin α5, cells 
were plated on glass coverslips for 48 h. The coverslips were washed, fixed, blocked, 
and labeled with mouse anti-EGFR antibody for 1 h at RT. Coverslips were washed 3 
times with PBS/0.1% Triton X-100 and incubated with secondary anti-mouse Alexa 647 
antibody or together with CTB-Alexa 555 for 1 h at RT in the dark. Cells were then 
washed and mounted. The confocal images were also acquiredusing a the 60×/1.35 NA 
oil immersion objective lens. For measurement of the co-localization, the Pearson's 
correlation coefficient between the proteins was measured in each image using ImageJ 
software (National Institutes of Health, version 1.47p). 
 
13. Biotinylation-based EGFR internalization assay.  
The indicated cells grown on 15-cm dishes were serum starved for 5 h prior to the assay 
and washed in ice-cold PBS, and surface proteins were biotinylated with 0.2 mg/ml 
Sulfo-NHS-SS Biotin in cold PBS for 1 h followed by washing in TBS and being placed 
on ice. For internalization, cells were then incubated in prewarmed DMEM containing 1 
ng/ml EGF and 0.3mM PQ at 37 °C for the indicated duration (0, 2.5, 5, 10, and 15 
min), whereas the control groups (-MesNa) remained on ice. Surface biotin was then 
stripped from the cells with 10 min incubation in 50 mM MesNa in TBS (pH 8.6) twice, 
followed by washing and quenching of the MesNa with 20 mM iodoacetamide in TBS 
for 10 min. The control group cells were not subjected to surface reduction (-MesNa) in 
order to obtain total surface-labeled EGFR. After quenching, the cells were lysed, 
precipitated with Streptavidin-conjugated agarose and subjected to WB. The percentage 
of internalized EGFR was calculated from the signal intensity of MesNa-resistant 
(internalized) EGFR at each time point relative to the control groups (-MesNa), which 
was the total EGFR on the cell surface in the 3 independent experiments.  
 
14. Xenograft assay.  
The left flank of NOD/SCID mice (5-week-old female mice; Charles River Laboratories, 
Japan) were injected subcutaneously with indicated cells (1×10
6
). After 21 days growth, 
tumors were dissected and their volumes and weights were noted. Tumor volumes were 
calculated using the formula V = (L × W
2
) × 0.5 (where V = volume, L = length, W = 
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width). All animal procedures were carried out according to experimental protocols 
approved by the Tohoku Pharmaceutical University Research Ethics Board. 
 
15. Statistical analysis.  
Results are presented as the mean ± s.e.m. Statistical analyses were performed using a 
Student’s t test using GraphPad Prism5. Statistical significance was defined as P <0.05 
(
n.s
P >0.05; *P <0.05; **P <0.01; ***P <0.001). 
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